Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19
Public ClinicalTrials.gov record NCT04343651. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate Coronavirus Disease 2019 (COVID-19)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with mild-to-moderate symptoms of respiratory illness caused by coronavirus 2019 infection.
Study identification
- NCT ID
- NCT04343651
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 86 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2020
- Primary completion
- Jul 20, 2020
- Completion
- Sep 19, 2021
- Last update posted
- Jan 3, 2023
2020 – 2021
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California, Los Angeles | Los Angeles | California | 90095 | — |
| Palmtree Clinical Research, Inc. | Palm Springs | California | 92262-4871 | — |
| Eisenhower Health | Rancho Mirage | California | 92270 | — |
| Yale | New Haven | Connecticut | 06510 | — |
| Center for Advanced Research & Education (CARE) | Gainesville | Georgia | 30501 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | — |
| Atlantic Health System Hospital | Morristown | New Jersey | 07962-1905 | — |
| Montefiore Medical Center | The Bronx | New York | 10467 | — |
| White Plains Hospital | White Plains | New York | 10601 | — |
| Novant Health | Charlotte | North Carolina | 27103 | — |
| Ohio Health | Columbus | Ohio | 43215 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Coronavirus Disease 2019 trials
Other public records listing Coronavirus Disease 2019. Sorted by last update posted; newest first. Not a recommendation.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04343651, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 3, 2023 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04343651 live on ClinicalTrials.gov.